ArticleBMC complementary medicine and therapies2025
Application value of baicalein in the management of periprosthetic joint infection: a preliminary in vitro study.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThis study aims to evaluate the efficacy of baicalein, a flavonoid derived from Scutellaria baicalensis, against Staphylococcus aureus (S. aureus), focusing on its inhibitory and eradicative effects on biofilms, as well as its cellular cytotoxicity. The goal is to provide preliminary evidence for its potential application in the management of periprosthetic joint infection (PJI).
methodsThe minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of baicalein against the standard strain of S. aureus ATCC 29213, a clinical strain of methicillin-sensitive S. aureus 115 (MSSA 115), and a clinical strain of methicillin-resistant S. aureus 49 (MRSA 49) were determined using broth microdilution and colony counting methods. Bactericidal kinetics over a 24-h period were evaluated using a time-kill assay. Biofilm inhibition and eradication were assessed on 96-well and titanium alloy plates, while the cellular cytotoxicity of baicalein was examined using the cell counting kit-8 (CCK-8) assay on human primary synovial fibroblasts and chondrocytes.
resultsThe MIC of baicalein was 32 μg/mL for the ATCC 29213, and 64 μg/mL for both MSSA115 and MRSA49. Meanwhile, the MBC for all three strains was 128 μg/mL. Baicalein exhibited a time-dependent bactericidal activity, with maximum efficacy at 24 h. Biofilm inhibition was evident at concentrations equal to or exceeding the MIC, as confirmed by biofilm biomass and metabolic activity assays, along with scanning electron and confocal laser microscope. However, baicalein was unable to completely eradicate preformed biofilms. Baicalein demonstrated significant cytotoxic effects on both synovial fibroblasts and chondrocytes after exposure for 16 and 24 h.
conclusionsBaicalein shows significant bactericidal effects and effectively inhibits S. aureus biofilm formation. These findings suggest its potential as a promising local antibacterial agent for postoperative continuous intra-articular lavage in the treatment of S. aureus-related early postoperative or acute hematogenous PJIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.